Paulson & Co’s Pfizer PFE Stock Holding History

Paulson & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-843,200	Closed	-$23.7M	–	92
2016 Q1	$23.7M	Buy	+843,200	New	+$24.1M	0.18%	50

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paulson & Co's PFE Position: Q2 2017 in Review

Paulson & Co sold out of Pfizer (PFE) in Q2 2017, closing a stake of 429,505 shares — an estimated $13.9M sold.

Paulson & Co first reported a position in PFE in Q4 2015 and held it in 6 quarters. The position peaked at $40.8M in Q1 2016. 2,050 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

Paulson & Co reported no remaining Pfizer position as of Q2 2017 after selling out during the quarter.
Paulson & Co sold 429,505 Pfizer shares in Q2 2017, an estimated $13.9M.
Paulson & Co first reported a position in Pfizer in Q4 2015 and held it in 6 quarters.
Paulson & Co's Pfizer position peaked at $40.8M in Q1 2016.
2,050 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Paulson & Co's 13F filing for Q2 2017, filed 14 Aug 2017.